{"id":68759,"date":"2026-06-23T23:42:18","date_gmt":"2026-06-23T15:42:18","guid":{"rendered":"https:\/\/flcube.com\/?p=68759"},"modified":"2026-06-23T23:42:20","modified_gmt":"2026-06-23T15:42:20","slug":"pfizer-reports-mixed-phase-3-results-for-sigvotatug-vedotin-in-non-small-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68759","title":{"rendered":"Pfizer Reports Mixed Phase 3 Results for Sigvotatug Vedotin in Non-Small Cell Lung Cancer"},"content":{"rendered":"\n

Pfizer Inc.<\/strong> (NYSE: PFE<\/a>) announced topline results from the Phase 3 SigVie-002 study<\/strong> (formerly Be6A Lung-01) evaluating sigvotatug vedotin<\/strong>, an investigational integrin beta-6 (IB6) directed antibody-drug conjugate (ADC)<\/strong> in patients with non-squamous non-small cell lung cancer (NSCLC)<\/strong>.<\/p>\n\n\n\n

Clinical Trial Overview<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Study Name<\/strong><\/td>SigVie-002 (previously Be6A Lung-01)<\/td><\/tr>
Phase<\/strong><\/td>Phase 3<\/td><\/tr>
Patient Population<\/strong><\/td>Adults with locally advanced, unresectable or metastatic non-squamous NSCLC<\/td><\/tr>
Prior Therapy<\/strong><\/td>One or more lines of systemic therapy<\/td><\/tr>
Comparator<\/strong><\/td>Docetaxel<\/td><\/tr>
Primary Endpoint<\/strong><\/td>Overall Survival (OS)<\/td><\/tr>
Announcement Date<\/strong><\/td>June 22, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Key Efficacy Findings<\/h2>\n\n\n\n